Anett Ullrich
Overview
Explore the profile of Anett Ullrich including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
119
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Brecklinghaus T, Albrecht W, Duda J, Kappenberg F, Grundler L, Edlund K, et al.
Toxicol Lett
. 2022 Aug;
368:33-46.
PMID: 35963427
The accumulation of lipid droplets in hepatocytes is a key feature of drug-induced liver injury (DILI) and can be induced by a subset of hepatotoxic compounds. In the present study,...
2.
Busche M, Tomilova O, Schutte J, Werner S, Beer M, Groll N, et al.
Lab Chip
. 2020 Jul;
20(16):2911-2926.
PMID: 32662810
HepaChip microplate (HepaChip-MP) is a microfluidic platform comprised of 24 independent culture chambers with continuous, unidirectional perfusion. In the HepaChip-MP, an automated dielectrophoresis process selectively assembles viable cells into elongated...
3.
Albrecht W, Kappenberg F, Brecklinghaus T, Stoeber R, Marchan R, Zhang M, et al.
Arch Toxicol
. 2019 Jun;
93(6):1609-1637.
PMID: 31250071
Drug-induced liver injury (DILI) cannot be accurately predicted by animal models. In addition, currently available in vitro methods do not allow for the estimation of hepatotoxic doses or the determination...
4.
Berlin S, Spieckermann L, Oswald S, Keiser M, Lumpe S, Ullrich A, et al.
Mol Pharm
. 2016 Jan;
13(3):1089-99.
PMID: 26808255
Drug interactions often result from multiple pharmacokinetic changes, such as after rifampicin (RIF) and clarithromycin (CLA) in the treatment of abscessing lung diseases. Comedication of RIF may interact with CLA...
5.
Dickens H, Ullrich A, Runge D, Mueller B, Olszewski U, Hamilton G
Mol Med Rep
. 2011 Apr;
1(4):459-64.
PMID: 21479432
cis-4-Hydroxy-L-proline (CHP) is being clinically evaluated as an anticancer drug. Since this compound targets the production of L-proline-rich proteins and critical L-proline residues, its impact on long-term cultures of human...
6.
Ullrich A, Stolz D, Ellis E, Strom S, Michalopoulos G, Hengstler J, et al.
ALTEX
. 2010 Apr;
26(4):295-302.
PMID: 20383475
Due to species differences, primary human hepatocytes are still the in vitro system of choice to analyse liver specific processes and functions. Human hepatocytes were cultured for several weeks in...
7.
Ullrich A, Berg C, Hengstler J, Runge D
ALTEX
. 2007 Mar;
24(1):35-40.
PMID: 17361319
Human hepatocytes are the in vitro system of choice to study drug-induced processes in man. Here, we present HEPAC(2): a standardised and validated culture system in which human hepatocytes are...
8.
Thedinga E, Ullrich A, Drechsler S, Niendorf R, Kob A, Runge D, et al.
ALTEX
. 2007 Mar;
24(1):22-34.
PMID: 17361318
Prediction of liver toxicity and compound responses continues to be a major challenge for the pharmaceutical industry. In vitro studies on liver cells have been developed to reduce or replace...
9.
Scheller C, Ullrich A, Lamla S, Dittmer U, Rethwilm A, Koutsilieri E
Ann N Y Acad Sci
. 2007 Mar;
1091:540-7.
PMID: 17341643
CpG oligodeoxynucleotides (CpG ODNs) bind to toll-like receptor-9 (TLR-9) and activate immune cells with antigen-presenting activity, including B cells and dendritic cells. Here we show that treatment of the latently...
10.
Scheller C, Knoferle J, Ullrich A, Prottengeier J, Racek T, Sopper S, et al.
J Cell Biochem
. 2005 Dec;
97(6):1350-61.
PMID: 16365881
CD95 (Fas/Apo-1) triggers apoptotic cell death via a caspase-dependent pathway. Inhibition of caspase activation blocks proapoptotic signaling and thus, prevents execution of apoptosis. Besides induction of apoptotic cell death, CD95...